1 |
Blagosklonny, M. V. (2004) Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 3, 1035-1042.
|
2 |
Kim, N., He, N., Kim, C., Zhang, F., Lu, Y., Yu, Q., Stemke-Hale, K., Greshock, J., Wooster, R., Yoon, S. and Mills, G. B. (2012) Systematic analysis of genotype-specific drug responses in cancer. Int. J. Cancer 131, 2456-2464.
DOI
ScienceOn
|
3 |
Scudiero, D. A., Shoemaker, R. H., Paull, K. D., Monks, A., Tierney, S., Nofziger, T. H., Currens, M. J., Seniff, D. and Boyd, M. R. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48, 4827-4833.
|
4 |
Kwei, K. A., Baker, J. B. and Pelham, R. J. (2012) Modulators of Sensitivity and Resistance to Inhibition of PI3K Identified in a Pharmacogenomic Screen of the NCI-60 Human Tumor Cell Line Collection. PLoS One 7, e46518.
DOI
|
5 |
Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. and Sadee, W. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491.
DOI
ScienceOn
|
6 |
Sausville, E. A. and Holbeck, S. L. (2004) Transcription profiling of gene expression in drug discovery and development: the NCI experience. Eur. J. Cancer 40, 2544-2549.
DOI
ScienceOn
|
7 |
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., Lee, C., Wagner, S. N., Li, C., Golub, T. R., Rimm, D. L., Meyerson, M. L., Fisher, D. E. and Sellers, W. R. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117-122.
DOI
ScienceOn
|
8 |
Blower, P. E., Verducci, J. S., Lin, S., Zhou, J., Chung, J. H., Dai, Z., Liu, C. G., Reinhold, W., Lorenzi, P. L., Kaldjian, E. P., Croce, C. M., Weinstein, J. N. and Sadee, W. (2007) MicroRNA expression profiles for the NCI-60 cancer cell panel. Mol. Cancer Ther. 6, 1483-1491.
DOI
ScienceOn
|
9 |
Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., Buck, G., Butler, A., Clements, J., Cole, J., Dicks, E., Forbes, S., Gray, K., Halliday, K., Harrison, R., Hills, K., Hinton, J., Hunter, C., Jenkinson, A., Jones, D., Kosmidou, V., Lugg, R., Menzies, A., Mironenko, T., Parker, A., Perry, J., Raine, K., Richardson, D., Shepherd, R., Small, A., Smith, R., Solomon, H., Stephens, P., Teague, J., Tofts, C., Varian, J., Webb, T., West, S., Widaa, S., Yates, A., Reinhold, W., Weinstein, J. N., Stratton, M. R., Futreal, P. A. and Wooster, R. (2006) Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5, 2606-2612.
DOI
ScienceOn
|
10 |
Nishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., Munson, P. J., Petricoin, E. 3rd, Liotta, L. A. and Weinstein, J. N. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc. Natl. Acad. Sci. U.S.A. 100, 14229-14234.
DOI
ScienceOn
|
11 |
Ehrich, M., Turner, J., Gibbs, P., Lipton, L., Giovanneti, M., Cantor, C. and van den Boom, D. (2008) Cytosine methylation profiling of cancer cell lines. Proc. Natl. Acad. Sci. U.S.A. 105, 4844-4849.
DOI
ScienceOn
|
12 |
Clavel, J. (2007) Progress in the epidemiological understanding of gene-environment interactions in major diseases: cancer. C. R. Biol. 330, 306-317.
DOI
ScienceOn
|
13 |
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T. and Bates, S. E. (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627-638.
|
14 |
Shankavaram, U. T., Reinhold, W. C., Nishizuka, S., Major, S., Morita, D., Chary, K. K., Reimers, M. A., Scherf, U., Kahn, A., Dolginow, D., Cossman, J., Kaldjian, E. P., Scudiero, D. A., Petricoin, E., Liotta, L., Lee, J. K. and Weinstein, J. N. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol. Cancer Ther. 6, 820-832.
DOI
ScienceOn
|
15 |
Lee, A. C., Shedden, K., Rosania, G. R. and Crippen, G. M. (2008) Data mining the NCI60 to predict generalized cytotoxicity. J. Chem. Inf. Model. 48, 1379-1388.
DOI
ScienceOn
|
16 |
Malumbres, M. (2007) Cyclins and related kinases in cancer cells. J. BUON 12(Suppl 1), S45-52.
|
17 |
Crow, R. T., Rosenbaum, B., Smith, R. 3rd, Guo, Y., Ramos, K. S. and Sulikowski, G. A. (1999) Landomycin A inhibits DNA synthesis and G1/S cell cycle progression. Bioorg. Med. Chem. Lett. 9, 1663-1666.
DOI
ScienceOn
|
18 |
Ahn, Y. J., Kim, H., Lim, H., Lee, M., Kang, Y., Moon, S., Kim, H. S. and Kim, H. H. (2012) AMP-activated protein kinase: implications on ischemic diseases. BMB Rep. 45, 489-495.
과학기술학회마을
DOI
ScienceOn
|
19 |
Keshavarz, P., Inoue, H., Nakamura, N., Yoshikawa, T., Tanahashi, T. and Itakura, M. (2008) Single nucleotide polymorphisms in genes encoding LKB1 (STK11), TORC2 (CRTC2) and AMPK alpha2-subunit (PRKAA2) and risk of type 2 diabetes. Mol. Genet. Metab. 93, 200-209.
DOI
ScienceOn
|
20 |
Uslu, R. and Bonavida, B. (1996) Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum. Cancer 77, 725-732.
DOI
|
21 |
Zhang, Z., Zhao, M., Li, Q., Zhao, H., Wang, J. and Li, Y. (2009) Acetyl-l-carnitine inhibits TNF-alpha-induced insulin resistance via AMPK pathway in rat skeletal muscle cells. Febs. Lett. 583, 470-474.
DOI
ScienceOn
|
22 |
Bonadona, V., Bonaiti, B., Olschwang, S., Grandjouan, S., Huiart, L., Longy, M., Guimbaud, R., Buecher, B., Bignon, Y. J., Caron, O., Colas, C., Nogues, C., Lejeune-Dumoulin, S., Olivier-Faivre, L., Polycarpe-Osaer, F., Nguyen, T. D., Desseigne, F., Saurin, J. C., Berthet, P., Leroux, D., Duffour, J., Manouvrier, S., Frebourg, T., Sobol, H., Lasset, C. and Bonaiti-Pellie, C. (2011) Cancer risks associated with germline mutations in MLH1, MSH2 and MSH6 genes in Lynch syndrome. JAMA 305, 2304-2310.
DOI
ScienceOn
|
23 |
Konstantinova, L. S., Bol'shakov, O. I., Obruchnikova, N. V., Laborie, H., Tanga, A., Sopena, V., Lanneluc, I., Picot, L., Sable, S., Thiery, V. and Rakitin, O. A. (2009) One-pot synthesis of 5-phenylimino, 5-thieno or 5-oxo-1,2,3-dithiazoles and evaluation of their antimicrobial and antitumor activity. Bioorg. Med. Chem. Lett. 19, 136-141.
DOI
ScienceOn
|
24 |
Lopez-Knowles, E., Zardawi, S. J., McNeil, C. M., Millar, E. K., Crea, P., Musgrove, E. A., Sutherland, R. L. and O'Toole, S. A. (2010) Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients. Cancer Epidemiol. Biomarkers Prev. 19, 301-309.
DOI
ScienceOn
|
25 |
Evidente, A., Kireev, A. S., Jenkins, A. R., Romero, A. E., Steelant, W. F., Van Slambrouck, S. and Kornienko, A. (2009) Biological evaluation of structurally diverse amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design. Planta Med. 75, 501-507.
DOI
ScienceOn
|
26 |
Ishihara, A., Yoshida, T., Tamaki, H. and Sakakura, T. (1995) Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. 1, 1035-1041.
|
27 |
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix- Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R. and Futreal, P. A. (2002) Mutations of the BRAF gene in human cancer. Nature 417, 949-954.
DOI
ScienceOn
|
28 |
Alonso, C. M., Such, E., Gomez-Segui, I., Cervera, J., Martinez-Cuadron, D., Luna, I., Ibanez, M., Lopez-Pavia, M., Vera, B., Navarro, I., Senent, L. and Sanz Alonso, M. A. (2012) BRAF V600E mutation in adult acute lymphoblastic leukemia. Leuk. Lymphoma [Epub ahead of print].
|
29 |
Ikediobi, O. N., Reimers, M., Durinck, S., Blower, P. E., Futreal, A. P., Stratton, M. R. and Weinstein, J. N. (2008) In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation. Mol. Cancer Ther. 7, 1337-1346.
DOI
ScienceOn
|
30 |
Scott, S. A., Dong, W. F., Ichinohasama, R., Hirsch, C., Sheridan, D., Sanche, S. E., Geyer, C. R. and Decoteau, J. F. (2006) 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Leuk. Res. 30, 69-76.
DOI
ScienceOn
|
31 |
Amatori, S., Papalini, F., Lazzarini, R., Donati, B., Bagaloni, I., Rippo, M. R., Procopio, A., Pelicci, P. G., Catalano, A. and Fanelli, M. (2009) Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. Lung Cancer 66, 184-190.
DOI
ScienceOn
|
32 |
de Hoon, M. J., Imoto, S., Nolan, J. and Miyano, S. (2004) Open source clustering software. Bioinformatics 20, 1453-1454.
DOI
ScienceOn
|
33 |
Cheng, T., Wang, Y. and Bryant, S. H. (2010) Investigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small molecules. Bioinformatics 26, 2881-2888.
DOI
ScienceOn
|
34 |
Kirchheiner, J., Fuhr, U. and Brockmoller, J. (2005) Pharmacogenetics- based therapeutic recommendations- ready for clinical practice? Nat. Rev. Drug Discov. 4, 639-647.
DOI
ScienceOn
|
35 |
Altmann, A., Daumer, M., Beerenwinkel, N., Peres, Y., Schulter, E., Buch, J., Rhee, S. Y., Sonnerborg, A., Fessel, W. J., Shafer, R. W., Zazzi, M., Kaiser, R. and Lengauer, T. (2009) Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database. J. Infect. Dis. 199, 999-1006.
DOI
ScienceOn
|
36 |
Eisen, M. B., Spellman, P. T., Brown, P. O. and Botstein, D. (1998) Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U.S.A. 95, 14863-14868.
DOI
ScienceOn
|